Breast cancer (early) - trastuzumab
Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
Summary
Trastuzumab treatment should be offered as an option for women with early-stage HER2-positive breast cancer after they have had surgery and chemotherapy (and sometimes radiotherapy). Trastuzumab should be given once every 3 weeks for 12 months, or until the breast cancer comes back, whichever is so ...
Correction
It has been brought to our attention that this guidance contained an error in section 1.3, where it stated that:
‘Cardiac functional assessments should be repeated every 3 months during trastuzumab treatment. If the LVEF drops by 10% from baseline and to below 50% then trastuzumab treatment should be suspended…?
This has now been amended so that it follows more closely the SPC for trastuzumab, as follows:
‘Cardiac functional assessments should be repeated every 3 months during trastuzumab treatment. If the LVEF drops by 10 percentage (ejection) points or more from baseline and to below 50% then trastuzumab treatment should be suspended…?
Electronic versions of the guidance have been amended below. Printed copies of the amended quick reference guide will be available shortly from the NHS Response Line; telephone 0870 1555 455 and quote reference number N1111.
Update to guidance
CG80 Early and locally advanced breast cancer updates the recommendations contained in this appraisal. NICE and the Department of Health are currently reviewing the future position on updating technology appraisals within clinical guidelines, with particular reference to implications for the funding direction on technology appraisals. In the meantime, the technology appraisal guidance remains available and should continue to be followed. The statutory funding direction remains in place for the recommendations contained in the technology appraisal guidance.
Guidance documents
Implementing this guidance
About this guidance
Technology appraisals TA107
Issued: August 2006